Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells

OBJECTIVE: Sorafenib is an oral multikinase inhibitor that has been proven effective as a single-agent therapy in hepatocellular carcinoma, and there is a strong rationale for investigating its use in combination with other agents. Vitamin K2 is nearly non-toxic to humans and has been shown to inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yafei, Zhang, Bicheng, Zhang, Anran, Zhao, Yong, Zhao, Jie, Liu, Jian, Gao, Jianfei, Fang, Dianchun, Rao, Zhiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2012
Materias:
Basic Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438252/
https://www.ncbi.nlm.nih.gov/pubmed/23018309
http://dx.doi.org/10.6061/clinics/2012(09)18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438252/
https://www.ncbi.nlm.nih.gov/pubmed/23018309
http://dx.doi.org/10.6061/clinics/2012(09)18

Ejemplares similares